In brief: C3, SSH, Axon
Wednesday, 30 November, 2005
Clinical Cell Culture's (ASX:CCE) co-founder Prof Fiona Wood will step down from the company's board on December 31. She will remain as a consultant, an R&D partner through her research vehicle the McComb Foundation, and a substantial shareholder.
Shareholders at SSH Medical's (ASX:SSH) AGM yesterday approved a resolution to change the company's name to BioLayer Corporation, the unlisted Brisbane-based materials sciences company it acquired earlier this month.
Axon Instruments founder and former CEO Dr Alan Finkel has been appointed to the ATSE Clunies Ross board of governors. Finkel is the first winner of an ATSE Clunies Ross award to join the board.
Alliance seeks to boost regional capacity in clinical trials
Launched this week, the Barwon Health–Deakin University Clinical Trials Alliance is...
Cartherics and Catalent announce enhanced partnership
To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
